Skip to content

The Efficacy of Group Cognitive Behavior Therapy for Irritable Bowel Syndrome: Randomized Controlled Trial

The Efficacy of Group Cognitive Behavior Therapy for Irritable Bowel Syndrome: Randomized Controlled Trial - Successful Use of CBT for IRrItable bowel syndrome (SUCIRI) project

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031710
Enrollment
112
Registered
2018-04-06
Start date
2018-05-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

irritable bowel syndrome

Interventions

Group Cognitive Behavioral Therapy for Irritable Bowel Syndrome (Once a week,90 minutes session,10 sessions) waiting list

Sponsors

Kyoto University
Lead Sponsor
National Center for Cognitive Behavior Therapy and Research
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.People diagnosed by gastroenterologist and have have moderate or severe symptoms remaining after receiving symptom-targeted pharmacotherapy for 3 months or more. 2.People diagnosed with irritable bowel syndrome based on the Rome III or Rome IV diagnostic criteria 3.People who basically do not change (as much as possible) usual treatment for IBS during the research 4.People who are capable of continuous hospital visits and motivated 5.People who can communicate, read and write in Japanese 6.Persons who can understand the purpose and content of this trial and give voluntary written informed consent

Exclusion criteria

Exclusion criteria: 1.People who has received psychotherapies 2.People who are currently undergoing treatment in psychiatry or psychosomatic department and judged that psychiatry or psychosomatic medicine doctor is inappropriate for participation in this study 3.People who are suffering from sever anxiety disorders and depression or with suicidal attempt (using PHQ-9) 4.Pregnant women 5.People who is treated or under treatment due to organic disease of the abdomen 6.People whom the principal investigator has determined to be unsuitable as a participant of the study

Design outcomes

Primary

MeasureTime frame
1.the IBS Symptom Severity Score (IBS-SSS) 2.the IBS-Quality of Life Measure (IBS-QOL)

Secondary

MeasureTime frame
1.Irritable Bowel Syndrome-Global Improvement Scale(Japanese:IBS-GIS) 2.EuroQol-5D-5L(Japanese:EQ-5D-5L) 3.Patient Health Questionnaire-9(Japanese:PHQ-9) 4.Generalized Anxiety Disorder-7(Japanese:GAD-7) 5.Gastrointestinal Symptom Rating Scale(Japanese:GSRS) 6.The Composite Primary Symptom Reduction(CPSR) 7.Dropout rate 8.Adverse Events

Countries

Japan

Contacts

Public ContactShino Kikuchi

Graduate school of Medicine and Faculty of Medicine Kyoto University Health Promotion and Human Behavior

suciri117@gmail.com090-8377-8549

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026